William Blair Expects Lower Earnings for ARS Pharmaceuticals

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Stock analysts at William Blair reduced their Q1 2025 earnings per share estimates for ARS Pharmaceuticals in a research report issued on Thursday, March 20th. William Blair analyst L. Hanbury-Brown now anticipates that the company will post earnings per share of ($0.35) for the quarter, down from their previous estimate of ($0.25). William Blair has a "Outperform" rating on the stock. The consensus estimate for ARS Pharmaceuticals' current full-year earnings is ($0.55) per share. William Blair also issued estimates for ARS Pharmaceuticals' Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.39) EPS and FY2026 earnings at ($0.14) EPS.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last posted its earnings results on Thursday, March 20th. The company reported $0.52 EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.56. The business had revenue of $86.58 million for the quarter, compared to analysts' expectations of $15.46 million.

Several other research firms have also commented on SPRY. Scotiabank assumed coverage on shares of ARS Pharmaceuticals in a report on Friday, March 7th. They issued a "sector outperform" rating and a $30.00 price target on the stock. Leerink Partners upped their price objective on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an "outperform" rating in a research note on Monday, January 13th. Raymond James upped their price target on ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a "strong-buy" rating in a research report on Tuesday, January 14th. Finally, Oppenheimer assumed coverage on ARS Pharmaceuticals in a research report on Monday, February 10th. They set an "outperform" rating and a $40.00 price objective on the stock. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $31.00.

ARS Pharmaceuticals Stock Up 0.2 %

Shares of ARS Pharmaceuticals stock traded up $0.03 during midday trading on Monday, hitting $12.63. The company had a trading volume of 1,549,751 shares, compared to its average volume of 1,067,730. The company has a fifty day simple moving average of $12.14 and a 200 day simple moving average of $13.07. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -24.76 and a beta of 1.03. ARS Pharmaceuticals has a 12-month low of $7.55 and a 12-month high of $18.51.

Insider Activity at ARS Pharmaceuticals

In related news, insider Eric Karas sold 10,000 shares of ARS Pharmaceuticals stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $14.00, for a total value of $140,000.00. Following the completion of the transaction, the insider now owns 7,696 shares in the company, valued at approximately $107,744. The trade was a 56.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Laura Shawver sold 50,000 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $12.31, for a total transaction of $615,500.00. Following the sale, the director now directly owns 210,346 shares in the company, valued at approximately $2,589,359.26. The trade was a 19.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 159,600 shares of company stock worth $1,866,516. 40.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ARS Pharmaceuticals

Several institutional investors have recently modified their holdings of SPRY. Alliancebernstein L.P. grew its holdings in ARS Pharmaceuticals by 5,168.4% during the 4th quarter. Alliancebernstein L.P. now owns 3,880,734 shares of the company's stock worth $40,942,000 after acquiring an additional 3,807,074 shares in the last quarter. Vanguard Group Inc. grew its position in shares of ARS Pharmaceuticals by 3.5% during the fourth quarter. Vanguard Group Inc. now owns 3,464,952 shares of the company's stock worth $36,555,000 after acquiring an additional 115,656 shares during the last quarter. State Street Corp increased its holdings in shares of ARS Pharmaceuticals by 10.4% in the 3rd quarter. State Street Corp now owns 2,049,542 shares of the company's stock valued at $29,718,000 after acquiring an additional 193,321 shares during the period. Alyeska Investment Group L.P. raised its position in ARS Pharmaceuticals by 903.0% in the 4th quarter. Alyeska Investment Group L.P. now owns 1,253,724 shares of the company's stock valued at $13,227,000 after purchasing an additional 1,128,724 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in ARS Pharmaceuticals by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 1,238,156 shares of the company's stock worth $13,066,000 after purchasing an additional 3,351 shares during the period. Institutional investors and hedge funds own 68.16% of the company's stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.